Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
The life sciences sector is facing a wide array of challenges, including the need to fund the long path of drug discovery from initial patent application through to product approval and protecting the benefits of that hard-won innovation. Our clients are at the forefront of that innovation, meeting medical need and taking life-saving or enhancing products to market worldwide.
They need a team of lawyers that understands the drug development process and the challenges innovators face. Our expert team understands the drug development process and the challenges faced, providing the right mix of skills and experience that helps them protect, develop and defend their intellectual property, collaborate with other sector players and raise the finance necessary to pursue their goals.
We work on a cross-border basis and our membership of the international network, Pangea Net, ensures we have the expertise and resources to support our clients' needs across a range of jurisdictions, including in emerging markets.
Our clients – range from funders of life sciences, private equity houses, drug development companies, multinational pharmaceuticals, diagnostics companies, medical device manufacturers and research universities.
Our people – many of our team have completed secondments to large pharmaceutical companies and have first-hand experience of their legal issues. Many have also had an interest in this sector since the start of their career, with the majority of our lawyers graduating with chemistry degrees.
Working in partnership – we work in close partnership with our clients to deliver a tailored and responsive service that exceeds expectations and, , achieving the desired results.
Complete solution – whether you require advice on restructuring, equity fundraising, debt finance, mergers, acquisitions, disposals, spin outs, collaborations, contracts, licensing, patents (including entitlement, validity, enforcement and freedom to operate issues), material transfer agreements, distribution agreements, clinical trial agreements, non-disclosure agreements or studentship agreements, we can provide specialist advice based on experience in this sector.
Risk management - we guide you on the many issues, risks and barriers in the life sciences sector, including regulatory compliance, contractual risks and managing stakeholder concerns.
The Patents Court has granted declarations that dosage regimens were obvious at the claimed priority dates of certain of AbbVie’s patents and patent applications.
In this short video Paula Dumbill brings you the latest in technology law, looking firstly at a recent case on software and the Commercial Agents Regulations.
Hear from commercial and technology lawyer, Richard Nicholas, to find out how Brexit affects commercial contracts – what is speculation and what you need to do right now.
The forums hosted at offices across the UK, covers areas of law that are most likely to affect you as an in house lawyer. In this short video Richard Nicholas, commercial and technology expert, discusses the key themes of his talk on changes in contract law.
Advising management on the acquisition of Quotient Clinical, a provider of outsourced, early stage drug development services to the pharmaceutical industry, from the Quotient Bioresearch Group by Bridgepoint Development Capital.
Advising Bioprojet Pharma S.á.r.l on the UK aspects of a £10.2 million acquisition of Lincoln Medical Limited, which provides drug delivery systems for the treatment of anaphylactic shock.
Acting on Crown Bioscience Inc’s acquisition of Precos - a leading pre-clinical research and development service provider with a focus on oncology.
Acting for a household name in the health sector in defence of allegations of patent infringement in respect of a therapeutically-crucial diagnostic test.
Acting for the Medical Research Council in relation to a £16 million investment in a leading life sciences company. Advising them in relation to the £16m further financing of Heptares Therapeutics, a leading UK based drug development company.
Advising Meridian Bioscience on a group restructuring to achieve significant costs savings, using the Cross Border Merger Regulations.
Advising on the £863 million sale of Astex Pharmaceuticals Inc., a Nasdaq listed drug development company to Japanese pharmaceutical company Otsuka.
Advising Source BioScience on the £1.6million acquisition of Motherwell-based Inverclyde Biologicals.
Acting for Source BioScience plc in respect of its £9.75 million equity fundraising, debt finance and successful recommended cash offer for AIM listed Vindon Healthcare plc.
Traditional challenges to the inventive step of a patent are based on an allegation that it would be obvious to take a step from a specific item of prior art to the claimed invention.
The Court of Appeal has handed down its judgment on the long-running Pregabalin saga.
In an unusual post-settlement judgment in Electromagnetic Geoservices ASA v Petroleum Geo-Services ASA and others, Mr Justice Birss took the opportunity to…
Keep up with the latest content from Browne Jacobson:
© Copyright Browne Jacobson LLP 2017 - All rights reserved